CA3037850A1 - Highly potent multimeric e-selectin antagonists - Google Patents

Highly potent multimeric e-selectin antagonists Download PDF

Info

Publication number
CA3037850A1
CA3037850A1 CA3037850A CA3037850A CA3037850A1 CA 3037850 A1 CA3037850 A1 CA 3037850A1 CA 3037850 A CA3037850 A CA 3037850A CA 3037850 A CA3037850 A CA 3037850A CA 3037850 A1 CA3037850 A1 CA 3037850A1
Authority
CA
Canada
Prior art keywords
chosen
compound
compound according
groups
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3037850A
Other languages
English (en)
French (fr)
Inventor
John L. Magnani
John M. Peterson
Myung-Gi Baek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of CA3037850A1 publication Critical patent/CA3037850A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3037850A 2016-10-07 2017-10-06 Highly potent multimeric e-selectin antagonists Pending CA3037850A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662405792P 2016-10-07 2016-10-07
US62/405,792 2016-10-07
US201762451415P 2017-01-27 2017-01-27
US62/451,415 2017-01-27
PCT/US2017/055648 WO2018068010A1 (en) 2016-10-07 2017-10-06 Highly potent multimeric e-selectin antagonists

Publications (1)

Publication Number Publication Date
CA3037850A1 true CA3037850A1 (en) 2018-04-12

Family

ID=60191469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3037850A Pending CA3037850A1 (en) 2016-10-07 2017-10-06 Highly potent multimeric e-selectin antagonists

Country Status (9)

Country Link
US (3) US11072625B2 (OSRAM)
EP (1) EP3522931A1 (OSRAM)
JP (1) JP7069136B2 (OSRAM)
KR (3) KR20240046288A (OSRAM)
CN (2) CN117298287A (OSRAM)
AU (2) AU2017341065B2 (OSRAM)
BR (1) BR112019006642A2 (OSRAM)
CA (1) CA3037850A1 (OSRAM)
WO (1) WO2018068010A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240046288A (ko) * 2016-10-07 2024-04-08 글리코미메틱스, 인크. 매우 강력한 다량체성 e-셀렉틴 길항물질
US11712446B2 (en) * 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
BR112020018184A2 (pt) 2018-03-05 2021-02-02 Glycomimetics, Inc. usos de compostos
WO2020123435A2 (en) 2018-12-10 2020-06-18 Glycomimetics, Inc. Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020150263A1 (en) 2019-01-14 2020-07-23 Magnani John L Selectin or galectin antagonists for treating cytokine release syndrome and crs-induced neurotoxicity
US20220220144A1 (en) * 2019-04-24 2022-07-14 Glycomimetics, Inc. Multimeric pan-selectin antagonists
WO2020219417A1 (en) * 2019-04-24 2020-10-29 Glycomimetics, Inc. Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
EP3997247A1 (en) 2019-07-12 2022-05-18 GlycoMimetics, Inc. Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
BR112022001847A2 (pt) * 2019-07-31 2022-03-29 Glycomimetics Inc Uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes
US20220265693A1 (en) 2019-07-31 2022-08-25 Glycomimetics, Inc. Use of e-selectin antagonists to enhance the survival of reconstituted, bone marrow-depleted hosts
US20230147312A1 (en) * 2020-03-27 2023-05-11 Glycomimetics, Inc. Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
EP4157285A1 (en) 2020-05-31 2023-04-05 GlycoMimetics, Inc. Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis
WO2021257398A1 (en) 2020-06-14 2021-12-23 Magnani John L Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
US20240269157A1 (en) 2021-08-03 2024-08-15 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7409399A (nl) 1973-07-19 1975-01-21 Rhone Poulenc Sa Werkwijze ter bereiding van thermostabiele har- sen en voorwerpen geheel of gedeeltelijk be- staande uit deze harsen.
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
DK17885D0 (da) 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US4876199A (en) 1985-04-04 1989-10-24 Fred Hutchinson Cancer Research Center Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain
US4851511A (en) 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
EP0249008B1 (de) 1986-05-09 1993-09-15 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5079353A (en) 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5632991A (en) 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
EP0381310A1 (en) 1989-01-30 1990-08-08 The Biomembrane Institute Monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides and method for production thereof
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP0585963A1 (en) 1989-05-23 1994-03-09 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to CMP-170 antigen on activated endothelial cells
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
AU8007791A (en) 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
ATE224911T1 (de) 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
US5648344A (en) 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
US5143712A (en) 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5211937A (en) 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
NZ240316A (en) 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
JPH06504619A (ja) 1990-11-23 1994-05-26 ザ ジェネラル ホスピタル コーポレーション 細胞接着蛋白質−糖質相互作用の阻害
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5318890A (en) 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
ATE245696T1 (de) 1991-05-06 2003-08-15 Genentech Inc Ein selectin ligand
US5646123A (en) 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
US5580858A (en) 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
WO1993005070A1 (en) 1991-09-10 1993-03-18 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
US5268364A (en) 1991-12-12 1993-12-07 The Biomembrane Institute Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification
WO1994004568A1 (en) 1991-12-18 1994-03-03 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
US5643873A (en) 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5591835A (en) 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
CA2100412A1 (en) 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
US5753617A (en) 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
US5519008A (en) 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
WO1994006442A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
EP0601417A3 (de) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5710123A (en) 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
ATE173630T1 (de) 1992-12-29 1998-12-15 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
US5412123A (en) 1993-02-08 1995-05-02 Glycomed Incorporated Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system
JP2716657B2 (ja) 1993-02-26 1998-02-18 株式会社ディ・ディ・エス研究所 接着分子ｅｌａｍ‐１に特異的結合能を有する化合物
WO1994020514A1 (fr) 1993-03-04 1994-09-15 Mect Corporation Compose associe au systeme de lewis, procede d'obtention de ce compose et anti-inflammatoire
US5527890A (en) 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
EP0700301B1 (en) 1993-05-05 1999-09-01 Affymax Technologies N.V. Peptides and compounds that bind to elam-1
HUT74506A (en) 1993-05-14 1997-01-28 Cytel Corp Sialyl lewis-x analogues as inhibitors of cellular adhesion
US5854218A (en) 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
SE9301677L (sv) 1993-05-14 1994-11-18 Kurt G I Nilsson Syntesmetod
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5976540A (en) 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
DK0730608T3 (da) 1993-05-17 2002-07-22 Avant Immunotherapeutics Inc Præparater omfattende komplementrelaterede proteiner og carbohydrater og fremgangsmåder til fremstilling og anvendelse af præparaterne
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5646248A (en) 1993-06-08 1997-07-08 La Jolla Cancer Research Foundation E-selection binding soluble lamp-1 polypeptide
US5750508A (en) 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5658880A (en) 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5837689A (en) 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5789385A (en) 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5679321A (en) 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
DK76193D0 (da) 1993-06-25 1993-06-25 Astra Ab Kulhydratderivater
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5508387A (en) 1993-08-04 1996-04-16 Glycomed Incorporated Selectin binding glycopeptides
US5827837A (en) 1993-08-20 1998-10-27 The Regents Of The University Of California Polyanion anti-inflammatory agents
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
WO1995010296A1 (en) 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5783693A (en) 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5663151A (en) 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
EP0671409A3 (de) 1994-03-11 1996-06-12 Hoechst Ag Malonsäurederivate mit antiadhäsiven Eigenschaften.
DE4408248A1 (de) 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
HUT77345A (hu) 1994-04-29 1998-03-30 Texas Biotechnology Corporation E-szelektin, P-szelektin vagy L-szelektin szialil-Lewis x-hez vagy szialil-Lewis a-hoz kapcsolódását gátló mannopiranoziloxi-bifenil származékok és ezeket tartalmazó gyógyszerkészítmények
US5486536A (en) 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
JPH0899989A (ja) 1994-09-30 1996-04-16 Akira Hasegawa 新規糖脂質誘導体およびその製造用中間体
DE4436164A1 (de) 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5639734A (en) 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
WO1996020204A1 (en) 1994-12-28 1996-07-04 Sumitomo Pharmaceuticals Company, Limited Lewis x derivative and process for producing the same
US20020040008A1 (en) 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US5527936A (en) 1995-02-17 1996-06-18 E. I. Du Pont De Nemours And Company Hydrosilylation of unsaturated compounds
GB9504065D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
AU6155896A (en) 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
IT1290779B1 (it) 1995-06-26 1998-12-10 Antonio Sacchetti Procedimento per il potenziamento delle attivita' terapeutiche di sostanze naturali (vitamine, minerali, erbe, fitopreparati, alimenti)
NZ311686A (en) 1995-06-29 2000-01-28 Novartis Ag Diglycosylated 1,2-diols as mimetics of sialyl-lewis x and sialyl-lewis a
US5876715A (en) 1995-08-17 1999-03-02 The Biomembrane Institute Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
DE19532902A1 (de) 1995-09-06 1997-03-13 Hoechst Ag Neuartige Glycomimetika als Selektin-Antagonisten und daraus hergestellte entzündungshemmend wirkende Arzneimittel
DE19537334A1 (de) 1995-10-09 1997-04-10 Hoechst Ag Antiadhäsive Piperidin- und Pyrrolidin-Carbonsäuren
WO1997014707A1 (en) 1995-10-18 1997-04-24 Cytel Corporation SIALYL Lex ANALOGUES AS INHIBITORS OF CELLULAR ADHESION
US5919769A (en) 1995-10-26 1999-07-06 Kanebo, Ltd Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same
US5747463A (en) 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
JPH09176047A (ja) 1995-12-25 1997-07-08 Unitika Ltd 外用医薬製剤
DE19602355A1 (de) 1996-01-24 1997-07-31 Hoechst Ag Mehrfach fucosylierte Dicarbonsäuren mit antiadhäsiven Eigenschaften
US6187754B1 (en) 1996-01-30 2001-02-13 Glycotech Corp. Sialyl-Lewisa and sialyl-Lewisx epitode analogues
AU1542397A (en) 1996-01-30 1997-08-22 Novartis Ag Sialyl-lewisa and sialyl-lewisx epitope analogues
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
EP0902681B1 (en) 1996-03-01 2002-05-22 The Regents of the University of California Inhibition of selectin binding
US6344545B1 (en) 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US5654412A (en) 1996-05-29 1997-08-05 Glycomed Incorporated Processes for the synthesis of sialyl Lewisx compounds
US5994402A (en) 1996-06-05 1999-11-30 Rotstein; Ori D. Anti-inflammatory and anti-pyretic method
US5919768A (en) 1996-06-26 1999-07-06 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
PL331286A1 (en) 1996-08-08 1999-07-05 Novartis Ag Modified oligosaccharides
US5830871A (en) 1996-10-28 1998-11-03 The Scripps Research Institute Inhibitors of E-, P- and L-selectin binding
GB9618520D0 (en) 1996-09-05 1996-10-16 Chiroscience Ltd Compounds and their therapeutic use
US6592872B1 (en) 1996-09-17 2003-07-15 The United States Of America As Represented By The Department Of Health And Human Services Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
DE69737562T2 (de) 1996-09-27 2007-12-27 The Trustees Of Columbia University In The City Of New York Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US6110897A (en) 1996-10-10 2000-08-29 Glycorex Ab Antiinflammatory cell adhesion inhibitors
WO1998021334A2 (en) 1996-11-13 1998-05-22 Morphogenesis, Inc. Antibody mg1 recognizing a small subset of human hematopoietic cells
WO1998037902A1 (en) 1997-02-28 1998-09-03 The Regents Of The University Of California Inhibition of cell-cell binding by lipid assemblies
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
SE9701127D0 (sv) 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes
JP3720520B2 (ja) 1997-03-27 2005-11-30 タカラバイオ株式会社 糖と標的物との相互作用の測定方法
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6193973B1 (en) 1997-08-22 2001-02-27 B. David Tuttle Dietary supplement for boosting energy and increasing muscular strength
US5948628A (en) 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU8967998A (en) 1998-02-25 1999-09-15 Hsc Research & Development Limited Partnership Antibiotic-ligand conjugates and methods of use thereof
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US6458777B1 (en) 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
US6265192B1 (en) 1998-03-20 2001-07-24 The Regents Of The University Of California Glycosly sulfortransferase-3
US6365365B1 (en) 1998-03-20 2002-04-02 The Regents Of The University Of California Method of determining whether an agent modulates glycosyl sulfotransferase-3
US6037333A (en) 1998-05-07 2000-03-14 Trustees Of Tufts College Microbe-inhibiting compositions
WO1999061055A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
JP2002518354A (ja) 1998-06-16 2002-06-25 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ 糖硫酸ペプチド、その合成方法および使用方法
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
WO2000017216A1 (fr) 1998-09-21 2000-03-30 Otsuka Pharmaceutical Co., Ltd. Derives de carboxymethylgalactose
US6960566B1 (en) 1998-11-06 2005-11-01 The Wister Institute of Anatomy and Biology Compositions and methods for treatment of cancer
DE69941031D1 (de) 1998-11-12 2009-08-06 Novolytics Inc Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
CA2408883A1 (en) 2000-05-19 2001-11-29 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US20020165178A1 (en) 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
EP1325123A4 (en) 2000-09-12 2004-07-21 Inst Genetics Llc INHIBITION OF STENOSIS OR RESTENOSIS USING P-SELECTINE ANTAGONISTS
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU2002219828A1 (en) 2000-11-14 2002-05-27 The General Hospital Corporation Blockade of T cell migration into epithelial GVHD target tissues
EP1337539A2 (en) 2000-11-29 2003-08-27 Bracco International B.V. Linkable sialyl lewis x analogs
US20020132220A1 (en) 2000-12-27 2002-09-19 Berens Kurt L. Use of selectin antagonists in organ preservation solutions
JP2005512505A (ja) 2001-03-28 2005-05-12 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 外因性タンパク質をサイトゾルに運搬する方法およびその使用
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7087212B2 (en) 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
AU2002337913A1 (en) 2001-10-19 2003-04-28 Richard D. Cummings Glycosulfopeptide inhibitors and methods of use thereof
AU2002357072A1 (en) 2001-12-07 2003-06-23 Centocor, Inc. Pseudo-antibody constructs
RU2325387C2 (ru) 2001-12-21 2008-05-27 Анормед Инк. Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина
US20030186942A1 (en) 2002-01-16 2003-10-02 Crooks Peter A. Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
CA2490703A1 (en) 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
EP1572963A4 (en) 2002-10-11 2007-08-22 Univ Maryland Biotech Inst SYNTHETIC VACCINES CARBOHYDRATE BASE AGAINST HIV
CA2511174A1 (en) 2002-12-20 2004-07-15 Glycomimetics, Inc. Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection
US6844125B2 (en) 2003-03-20 2005-01-18 Kabushiki Kaisha Toshiba Combination of developing agents, image forming apparatus, and method for forming image
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US20040219158A1 (en) 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050214283A1 (en) 2003-11-07 2005-09-29 Robert Sackstein Antibodies to CD44 glycoforms and uses thereof
CA2546784A1 (en) 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
WO2005051920A2 (en) 2003-11-19 2005-06-09 Glycomimetics, Inc. Specific antagonist for both e- and p-selectins
CA2549074A1 (en) 2003-12-18 2005-06-30 Unibioscreen S.A. Glycosylated steroid derivatives with anti-migratory activity
GB0404434D0 (en) 2004-02-27 2004-03-31 Novartis Ag Organic compounds
US7745421B2 (en) 2004-05-25 2010-06-29 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells
CA2571431A1 (en) 2004-06-24 2006-01-05 The Scripps Research Institute Arrays with cleavable linkers
WO2006017180A2 (en) 2004-07-09 2006-02-16 Progenics Pharmaceuticals, Inc. Glycopeptide dimers and uses thereof
US7951816B2 (en) 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2006062946A2 (en) 2004-12-06 2006-06-15 University Of Florida Research Foundation, Inc. Incorporation of bone marrow derived stem cells in tumors
CA2593612A1 (en) 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of hiv infection
MX2007008328A (es) 2005-01-07 2008-01-16 Univ Emory Antagonistas cxcr4 para el tratamiento de trastornos medicos.
CA2598409A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2006105019A1 (en) 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
US20090036386A1 (en) 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
US20060287253A1 (en) 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
MX2008000974A (es) 2005-07-22 2008-03-27 Univ California Composiciones de heparina e inhibicion de selectina.
JP5175190B2 (ja) 2005-08-09 2013-04-03 グリコミメティクス， インコーポレイテッド シュードモナス由来のｐａ−ｉｌレクチン、ｐａ−ｉｉｌレクチンまたは両方のレクチンのグリコミメティック阻害剤
CA2618990A1 (en) 2005-08-15 2007-02-22 The Scripps Research Institute Methods to identify therapeutic agents useful for treating and preventing atherosclerosis by counteracting the effect of cholesterol ozonation products
US20080234294A1 (en) 2005-08-18 2008-09-25 Novartis Ag Cxcr4 Binding Molecules
US7728117B2 (en) 2005-09-02 2010-06-01 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
WO2007033329A1 (en) 2005-09-14 2007-03-22 University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech.Dev. Synthetic polyvalent carbohydrates as components of microbicides
WO2007143052A1 (en) 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
EP3461499A1 (en) 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
US20090175792A1 (en) 2006-06-23 2009-07-09 Glycomimetics, Inc. Glycomimetic inhibitors of siglec-8
WO2008008852A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including heteroatoms for the treatment of medical disorders
US20080227799A1 (en) 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
WO2008011094A2 (en) 2006-07-18 2008-01-24 Robert Sackstein Cytokine induction of selectin ligands on cells
JP5298020B2 (ja) * 2006-10-12 2013-09-25 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの糖模倣体置換
US20080306098A1 (en) 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
WO2008087259A1 (en) 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US8026222B2 (en) 2007-02-09 2011-09-27 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
WO2008109154A1 (en) 2007-03-08 2008-09-12 Altiris Therapeutics, Inc. Chemokine receptor modulators
US20090054334A1 (en) 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US20100303766A1 (en) 2007-08-08 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Cell population with enhanced transplantation activity
CN101918041A (zh) 2007-10-12 2010-12-15 超分子有限公司 用于肿瘤诊断和治疗的氯毒素剂的系统性给药
FI20070853A0 (fi) 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
US9486497B2 (en) 2007-12-10 2016-11-08 The University Of Queensland Treatment of immunocompromised conditions
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
AU2009257536B2 (en) 2008-06-13 2015-07-02 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
US20110245265A1 (en) 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
US20100240773A1 (en) 2009-03-23 2010-09-23 Kenneth Korzekwa Multifunctional linkers
FI20095459A0 (fi) 2009-04-24 2009-04-24 Suomen Punainen Risti Veripalv Uusia määritysmenetelmiä
WO2010126888A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2010132315A1 (en) 2009-05-13 2010-11-18 Endgenitor Technologies, Inc. Enhanced hematopoietic stem cell engraftment
US20110251148A1 (en) 2010-04-07 2011-10-13 Glycomimetics, Inc. Glycomimetic compounds and methods to inhibit infection by hiv
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
WO2012047918A1 (en) 2010-10-04 2012-04-12 Glycomimetics, Inc. Anti-epileptogenic agents
FI20106031A0 (fi) 2010-10-06 2010-10-06 Suomen Punainen Risti Veripalv Menetelmä solujen eristämiseksi ja menetelmällä eristetty solupopulaatio
WO2012061662A1 (en) 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
US8765126B2 (en) 2011-05-05 2014-07-01 Robert Sackstein Methods of treating complications and disorders associated with G-CSF administration
WO2013090926A1 (en) 2011-12-16 2013-06-20 Rembach Paul F System and method for cooling and maintaining building containing heat generating electronics
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
EP2914610A2 (en) 2012-10-31 2015-09-09 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
LT2928476T (lt) 2012-12-07 2018-05-25 Glycomimetics, Inc. Junginiai, kompozicijos ir būdai, naudojant e-selektino antagonistus, hemopoetinių ląstelių mobilizacijai
WO2014149837A1 (en) 2013-03-15 2014-09-25 Glycomimetics, Inc. Compounds and methods to enhance the oral availability of glycomimetics
JP2016527303A (ja) 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
CN105683208A (zh) 2013-09-30 2016-06-15 糖模拟物有限公司 治疗和/或预防粘膜炎的方法和组合物
US20160333043A1 (en) 2014-01-17 2016-11-17 Glycomimetics, Inc. E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
WO2016164394A1 (en) 2015-04-08 2016-10-13 Glycomimetics, Inc. 2-halo-galactose-containing selectin antagonists
US20180228871A1 (en) 2015-08-03 2018-08-16 Glycomimetics, Inc. Methods for the mobilization and use of t-cells with enhanced reconstitution potential and life-span
CA2950088A1 (en) 2015-12-02 2017-06-02 Glycomimetics, Inc. Heterobifunctional compounds having a triazole linker and e and/or p selectin binding affinity
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
KR20240046288A (ko) * 2016-10-07 2024-04-08 글리코미메틱스, 인크. 매우 강력한 다량체성 e-셀렉틴 길항물질
BR112022001847A2 (pt) * 2019-07-31 2022-03-29 Glycomimetics Inc Uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes

Also Published As

Publication number Publication date
US11780873B2 (en) 2023-10-10
KR20230164235A (ko) 2023-12-01
AU2017341065A1 (en) 2019-04-18
US20190233458A1 (en) 2019-08-01
US20230365609A1 (en) 2023-11-16
CN117298287A (zh) 2023-12-29
KR102607640B1 (ko) 2023-11-28
BR112019006642A2 (pt) 2019-07-02
EP3522931A1 (en) 2019-08-14
JP7069136B2 (ja) 2022-05-17
US11072625B2 (en) 2021-07-27
KR20190062509A (ko) 2019-06-05
CN109890421B (zh) 2023-10-20
US20210323990A1 (en) 2021-10-21
CN109890421A (zh) 2019-06-14
KR102653723B1 (ko) 2024-04-01
AU2017341065B2 (en) 2023-04-06
KR20240046288A (ko) 2024-04-08
AU2023204344A1 (en) 2023-07-27
JP2019529518A (ja) 2019-10-17
WO2018068010A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
CA3037850A1 (en) Highly potent multimeric e-selectin antagonists
US11878026B2 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
AU2018395417B2 (en) Heterobifunctional inhibitors of E-selectin and galectin-3
US20240150388A1 (en) Heterobifunctional inhibitors of e-selectin and galectin-3
US20160333043A1 (en) E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose
US20220073555A1 (en) Galectin-3 inhibiting c-glycosides
CA3136661A1 (en) Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
WO2021086816A1 (en) Galectin-3 inhibiting c-glycosides
US20240287121A1 (en) Galectin-3 inhibiting c-glycoside oximes
US20240270724A1 (en) Galectin-3 inhibiting c-glycosides
US20230091472A1 (en) Galectin-3 inhibiting c-glycoside ketones, ethers, and alcohols
WO2017205269A1 (en) Haloalkyl fucose-containing selectin antagonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

EEER Examination request

Effective date: 20220927

EEER Examination request

Effective date: 20220927

EEER Examination request

Effective date: 20220927